# Ben Auspitz

> Ben Auspitz is a Series A investor at Compass Therapeutics backing Biotechnology and Therapeutics. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Compass Therapeutics](https://shizune.co/investors/profile/compass-therapeutics)
- Location: Boston, United States
- Total investments: 11
- Last investment: Mar 2026
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ben-auspitz-79ab456/

Ben Auspitz is a Series A investor at Compass Therapeutics in Boston focused on Biotechnology and Therapeutics. Ben is a Partner at F-Prime Capital and has worked in pharmaceuticals and life science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up toa publicly-listed company. In this role, he oversaw the advancement of seven programs from the assay stage into phase II clinical studies and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics.He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals, and Compass Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ: DMTX), and Ultragenyx (NASDAQ: RARE)

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 73% |
| Therapeutics | 5 | 45% |
| Pharmaceutical | 4 | 36% |
| Medical | 3 | 27% |
| Health Care | 3 | 27% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 36% |
| Series B | 4 | 36% |
| Series C | 1 | 9% |
| Funding Round | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 64% |
| United Kingdom | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| R1 Therapeutics | R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M | Series A | Mar 17, 2026 |  |
| Checkmate Pharmaceuticals | Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapiesdesigned to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers.Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts. | $85M | Series C | Jun 10, 2020 |  |
| Checkmate Pharmaceuticals | Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapiesdesigned to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers.Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts. | $22M | Series C | Dec 12, 2018 |  |
| Avidity Biosciences | Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M | Series B | Oct 17, 2018 |  |
| Modis Therapeutics | Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases. | $30M | Series A | Oct 01, 2018 |  |
| Compass Therapeutics | Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $49M | Series A | Jul 12, 2018 |  |
| Indalo Therapeutics | Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of aseasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space. | $9M |  | Aug 02, 2017 |  |
| Checkmate Pharmaceuticals | Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapiesdesigned to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers.Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts. | $27M | Series B | Jun 15, 2017 |  |
| Dimension Therapeutics | Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with leadprograms in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences. | $65M | Series B | Apr 21, 2015 |  |
| Ultragenyx Pharmaceutical | Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team'sexperience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications. | $75M | Series B | Dec 31, 2012 |  |

10 of 11 investments shown.

## Co-investors
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 3 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together

## About Compass Therapeutics

VC Fund · Boston, United States

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

4 contacts available at Compass Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Ben Auspitz | Director | https://shizune.co/investors/profile/ben-auspitz |
| David Weisburd | Investor | https://shizune.co/investors/profile/david-weisburd |
| Errik Anderson | Co-Founder, President/COO | https://shizune.co/investors/profile/errik-anderson |
| Thomas Schuetz | CEO & Co-Founder | https://shizune.co/investors/profile/thomas-j-schuetz |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ben Auspitz invest in?

Ben Auspitz invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ben Auspitz last invest?

The most recent investment recorded for Ben Auspitz closed in Mar 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co